Replies to post #32340 on PharmaCyte Biotech Inc (PMCB)

[Hotelier51]

Well see that's pretty incorrect. Bavarian Nordic owned the rights with the Austrianova patent holders in the 1990s. BA is quite large. They abandoned it in the early 2000s. Austrianova went on it's own and failed, even after Orphan status was granted in 2003. They obtained funding from outside parties, but it led nowhere and to no progress. And they had 30x more money than Nuvilex/Pharmacyte has right now.

A few other companies developed similar products and again, abandoned it because it because obsolete based on where everything was headed.

You're looking at a bread and butter product nearly 20 years old and was partially sold off to a group of penny stock hucksters.

[Peacefulwendy]

Very nice post, Newbigtech...

Well put and puts everything in the proper perspective...

It is Cell-in-a-Box(R)'s time now as we will soon know for certainty when we hear about the extended study with TD2 and the subsequent Phase 1.

I had no doubt about the certainty of this technology when we heard the first study went very well. At that time we knew we performed better than current treatments just as we had done in the past.

Thanks

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

http://www.cancer-therapy.org/CT/v1/A/13%20%20L%C3%B6hr%20et%20al,%20121-131%20cop.pdf